While FGFR alterations other than FGFR2/3 point mutations or fusions have not yet been approved as predictive biomarkers in urinary tract carcinomas, these were reported in the anticipation of potential future evidence supporting their therapeutic value. Here, FGFR2 is linked to urothelial carcinoma.